Annotation
This is a Chinese company founded in 2017, offering high-quality recombinant protein for research use. Up until now, its core product is ESAT6 (early secreted antigenic target 6-kDa protein) -CFP10 (culture filtrate protein of 10 kDa) recombinant protein. The company is seeking partnership with potential foreign partners, and those from Europe in particular. The desired ways of cooperation include the signing of a distribution or commercial agency agreement.
Offer description
The innovative Chinese company focused on bio-technology was established in 2017. It offers high-quality recombinant protein for research use. By far, ESAT6 (early secreted antigenic target 6-kDa protein) -CFP10 (culture filtrate protein of 10 kDa) recombinant protein makes its core product. The company’s products enable research institutions to acquire more accurate experimental results and greatly improve the research and development success in the biomedical area. The product has been used by research institutions in China. Early secreted antigenic target 6-kDa protein (ESAT6) and culture filtrate protein of 10 kDa (CFP10) are two major M. tuberculosis-specific antigens, which have been reported to play key roles in the virulence of M. tuberculosis and elicit strong T-cell responses. A phase II clinical trial showed that the specificity of recombinant ESAT6 and CFP10 as the skin test reagent for the diagnosis of M. tuberculosis infection was 99.3%. Thus, the recombinant fusion protein ESAT6-CFP10 was expected to be an optimized skin test reagent for the diagnosis of M. tuberculosis infection. Now, the ESAT6-CFP10 recombinant protein products by the Chinese company are open to business partnership through the signing of a distribution or commercial agency agreement. The confirmed partners are expected to work with the Chinese company to jointly explore and sevice the local market.
Innovations and advantages
ESAT6-CFP10 recombinant protein is generated with the correct folding, matching the in-vivo situation. It is expressed in Escherichia coli and the protein carries no purification tags. The recombinant protein is purified without label and the purity is over 95%.
Market application codes
05005013 Emergency medicine
05007002 Pharmaceuticals/fine chemicals
Profile date
22.09.2021
Сотрудничество
Type of partner sought
The potential partner being sought is expected to have the required technical expertise and sales networks in vaccines and disease detection to be able to integrate these into the new type of ESAT6-CFP10 offered by the company. After signing an non-disclosure agreement, the Chinese company will send the interested party a specification of their products with all details. The confirmed partner will be the Chinese company's distributor or agent in the assigned foreign market.
Поделиться